Correction: König et al. Cefiderocol in critically ill patients with multi-drug resistant pathogens: Real-life data on pharmacokinetics and microbiological surveillance. Antibiotics 2021, 10, 649

Abstract

1. Text Correction 1.1 Based on the initial data from Table 1 there were errors in the original article [1]: “Five patients were included into the study, four were men, the median age was 53 years (range 35 to 76)”. has been corrected to Results, Individual Patients, and Paragraph 1: “Five patients were included into the study, four were men, the median age was 55 years (range 41 to 76)”. 1.2 In addition, the statement regarding patient #1: “Therapy with cefiderocol accompanied by TDM was initiated with a dose of 2 g eight hourly”, has been corrected to: Results, Individual Patients, Paragraph 2, Patient #1: “Therapy with cefiderocol accompanied by TDM and dose adaptions was initiated with a dose of 1 g eight hourly administered in prolonged infusion mode according to the manufactures’ instructions”. 1.3 The statements in patient #2: “Therapy with cefiderocol adapted for renal insufficiency accompanied by TDM was initiated with a dose of 1 g eight hourly administered in prolonged infusion mode.”, has been corrected to: Results, Individual Patients, Paragraph 2, Patient #2: “Therapy with cefiderocol adapted for renal insufficiency accompanied by TDM was initiated with a dose of 1 g eight hourly administered in prolonged infusion mode after a loading dose of 3 × 2 g for 24 h”. 1.4 Furthermore, the statement regarding patient #3: “On day 4 CRRT was initiated due to acute renal failure”. is incorrect and has been deleted. 1.5 The sentence: “After the first dose the treatment was extended by cytokine adsorber therapy with (CytoSorb®, Monmouth Junction, NJ, USA).”, has been corrected to: Results, Individual Patient, Paragraph 2, Patient #5: “After the first dose the treatment was extended by cytokine adsorber therapy (CytoSorb®, Monmouth Junction, NJ, USA)”. 1.6 The statement: “Samples for TDM were collected on day two of cefiderocol treatment initiation and repeated with occurrence of either dose adjustment or alteration in renal function including initiation of extracorporeal organ support.”, has been corrected to: Materials and Methods, 4.3 Cefiderocol Quantification:“Samples for TDM were collected from the beginning of cefiderocol treatment initiation and repeated with occurrence of either dose adjustment or alteration in renal function including initiation of extracorporeal organ support”. 1.7 The statement: “These findings, confirm the high variability in drug elimination in the vulnerable cohort of critically ill patients.”, has been corrected to: 3. Discussion: “These findings do confirm the high variability in drug elimination in the vulnerable cohort of critically ill patients”. The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. The original article has been updated.